Picture of Neogenomics logo

NEO Neogenomics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Annual cashflow statement for Neogenomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line8.014.17-8.35-144-88
Depreciation
Amortisation
Non-Cash Items17.523.3-66.740.538.9
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-32.4-61.7-4.99-31.7-25.5
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities23.41.46-26.7-66-1.95
Capital Expenditures-20-29.1-64.1-30.9-28.8
Purchase of Fixed Assets
Other Investing Cash Flow Items0.399-130-56831.4105
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-19.6-159-6320.51776.7
Financing Cash Flow Items-1.06-3.32-29.300
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities15923672511.84.55
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash16377.666.2-53.679.3